INSULIN AND DIDECANOYL-L-ALPHA-PHOSPHATIDYLCHOLINE - INVITRO STUDY OF THE TRANSPORT THROUGH RABBIT NASAL MUCOSAL TISSUE

被引:21
作者
BECHGAARD, E
JORGENSEN, L
LARSEN, R
GIZURARSON, S
CARSTENSEN, J
HVASS, A
机构
[1] CARLBIOTECH LTD AS,DK-2200 COPENHAGEN N,DENMARK
[2] LYFJATHROUN HF,ICELAND BIOPHARMACEUT GRP,IS-107 REYKJAVIK,ICELAND
[3] NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK
关键词
USSING CHAMBER; INSULIN; DIDECANOYL-L-ALPHA-PHOSPHATIDYLCHOLINE; NASAL ADMINISTRATION; ABSORPTION; RABBIT;
D O I
10.1016/0378-5173(93)90116-W
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Transport over rabbit nasal mucosal tissue of insulin and the absorption enhancer didecanoyl-L-alpha-phosphatidylcholine (DDPC) from an aqueous nasal insulin preparation were studied in vitro using the Ussing chamber. The appearance of insulin at the serosal side is expressed as parts per thousand of the initial insulin concentration (8 mg/ml) at the mucosal side. Mean appearance rate was 0.67 +/- 0.53 parts per thousand h-1, equivalent to an apparent penetration coefficient (P(app)) of 0.37 x 10(-6) cm/s. Corrected for possible degradation and/or adsorption at the serosal side the value is 0.91 +/- 0.79 parts per thousand h-1 (P(app) = 0.50 x 10(-6) cm/s). Addition of 20 mg DDPC/ml increased the insulin concentration a factor of only 1.3-1.5, indicating that the Ussing chamber method may not always be able to identify penetration enhancers. The concentrations of insulin and DDPC at the mucosal side between 5 and 90 min were relatively constant, the average recovery being about 85%. No transport of DDPC through the nasal tissue, using an initial mucosal concentration of 20 mg/ml, was observed. The sensitivity of the whole system was 240 mug cm-2 h-1, or 1.2% h-1. P(app) is therefore lower than 0.33 X 10(-5) cm/s. The sensitivity of the system is limited by disappearance of DDPC at the serosal side.
引用
收藏
页码:147 / 153
页数:7
相关论文
共 13 条
  • [1] ANSELL GB, 1982, PHOSPHOLIPIDS, P1
  • [2] THE VIABILITY OF ISOLATED RABBIT NASAL-MUCOSA IN THE USSING CHAMBER, AND THE PERMEABILITY OF INSULIN ACROSS THE MEMBRANE
    BECHGAARD, E
    GIZURARSON, S
    JORGENSEN, L
    LARSEN, R
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 87 (1-3) : 125 - 132
  • [3] CARSTENS S, 1992, BUCCAL AND NASAL ADMINISTRATION AS AN ALTERNATIVE TO PARENTERAL ADMINISTRATION: EUROPEAN SYMPOSIUM, MINUTES, P264
  • [4] DREJER K, 1990, Diabetologia, V33, pA61
  • [5] THE INFLUENCE OF INSULIN AND SOME EXCIPIENTS USED IN NASAL INSULIN PREPARATIONS ON MUCOCILIARY CLEARANCE
    GIZURARSON, S
    MARRIOTT, C
    MARTIN, GP
    BECHGAARD, E
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 65 (03) : 243 - 247
  • [6] GIZURARSON S, 1991, CHEM PHARM BULL, V39, P2155
  • [7] HANSEN P, 1988, Diabetes Research and Clinical Practice, V5, pS164
  • [8] EFFECTS OF ABSORPTION ENHANCERS ON HUMAN NASAL TISSUE CILIARY MOVEMENT INVITRO
    HERMENS, WAJJ
    HOOYMANS, PM
    VERHOEF, JC
    MERKUS, FWHM
    [J]. PHARMACEUTICAL RESEARCH, 1990, 7 (02) : 144 - 146
  • [9] HIRAI S, 1981, INT J PHARM, V9, P173
  • [10] ANALYSIS OF STRUCTURAL REQUIREMENTS FOR THE ABSORPTION OF DRUGS AND MACROMOLECULES FROM THE NASAL CAVITY
    MCMARTIN, C
    HUTCHINSON, LEF
    HYDE, R
    PETERS, GE
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (07) : 535 - 540